Drugs

, Volume 74, Issue 12, pp 1379–1410

Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases

Adis Drug Evaluation

Abstract

With its approval more than 15 years ago, subcutaneous etanercept (Enbrel®) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis, and in paediatric patients with juvenile idiopathic arthritis or plaque psoriasis. In all of these populations, etanercept (with or without methotrexate) effectively reduced signs and symptoms, disease activity and disability, and improved health-related quality of life, with these benefits sustained during long-term treatment. The safety profile of etanercept during short- and long-term treatment was consistent with the approved product labelling, with adverse events being of a predictable and manageable nature. The introduction of etanercept and other bDMARDs as therapeutic options for patients with autoimmune rheumatic diseases and spondyloarthropathies revolutionized disease management and these agents continue to have a central role in treatment strategies. This article reviews the extensive clinical experience with etanercept in these patient populations.

References

  1. 1.
    Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.PubMedGoogle Scholar
  3. 3.
    National Institute for Health and Clinical Excellence. CG153 Psoriasis: NICE guideline. 2012. http://guidance.nice.org.uk/CG153/NICEGuidance/pdf/English. Accessed 18 Apr 2014.
  4. 4.
    Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:897–1019.Google Scholar
  5. 5.
    Strand V, Sharp V, Koenig AS, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012;71(7):1143–50.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Boehncke WH, Qureshi A, Merola JF, et al. Diagnosing and treating psoriatic arthritis: an update. Br J Dermatol. 2014;170(4):772–86.PubMedGoogle Scholar
  7. 7.
    Emery P, Sebba A, Huizinga TWJ. Biologic and oral disease modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72:1897–904.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17(9 Suppl B):S14–8.Google Scholar
  9. 9.
    McKeage K. A review of CT-P-13: an inflixmab biosimilar. BioDrugs. 2014;. doi:10.1007/s40259-014-0094-1.PubMedGoogle Scholar
  10. 10.
    Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacologic therapies. Ann Rheum Dis. 2012;71:4–12.PubMedGoogle Scholar
  11. 11.
    Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparisons of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2013. doi:10.1136/annrheumdis-2013-204128.Google Scholar
  13. 13.
    Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs. 1999;57(6):945–66.PubMedGoogle Scholar
  14. 14.
    Culy CR, Keating GM. Etanercept: a review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs Aging. 2002;62(17):2493–537.Google Scholar
  15. 15.
    McCormack PL, Wellington K. Etanercept: in ankylosing spondyltits. BioDrugs. 2004;18(3):199–205.PubMedGoogle Scholar
  16. 16.
    Goldsmith DR, Wagstaff AJ. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2005;6(2):121–36.PubMedGoogle Scholar
  17. 17.
    Hoy SM, Scott LJ. Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis. Drugs. 2007;67(17):2609–33.PubMedGoogle Scholar
  18. 18.
    Dhillon S, Lyseng-Williamson KA, Scott LJ. Etanercept: a review of its use in the management of rheumatoid arthritis. Drugs. 2007;67(8):1211–41.PubMedGoogle Scholar
  19. 19.
    European Medicines Agency. Enbrel 25 mg powder and solvent solution for injection: summary of product characteristics. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf. Accessed 15 Apr 2014.
  20. 20.
    Amgen. Enbrel (etanercept) solution for subcutaneous use: US prescribing information. 2013. http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf. Accessed 15 Apr 2014.
  21. 21.
    Hsu L, Snodgrass BT, Armstrong AW. Anti-drug antibodies in psoriasis: a systematic review. Br J Dermatol. 2013. doi:10.1111/bjd.12654.PubMedGoogle Scholar
  22. 22.
    Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72:165–78.PubMedGoogle Scholar
  23. 23.
    van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenecity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164–72.PubMedGoogle Scholar
  24. 24.
    Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375–82.PubMedGoogle Scholar
  25. 25.
    Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–93.PubMedGoogle Scholar
  26. 26.
    Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis. 2012;71(6):989–92.PubMedGoogle Scholar
  27. 27.
    Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res. 2011;63(3):373–82.Google Scholar
  28. 28.
    Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005;32(7):1232–42.PubMedGoogle Scholar
  29. 29.
    Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46(6):1443–50.PubMedGoogle Scholar
  30. 30.
    Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care. 2002;8(3):231–40.PubMedGoogle Scholar
  31. 31.
    Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial [Erratum appears in Ann Rheum Dis. 2011 Aug; 70(8):1519]. Ann Rheum Dis. 2010;69(1):222–5.PubMedGoogle Scholar
  32. 32.
    Anis A, Zhang W, Emery P, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology. 2009;48(10):1283–9.PubMedGoogle Scholar
  33. 33.
    Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study [Erratum appears in Arthritis Rheum. 2010 Oct; 62(10):3005]. Arthritis Rheum. 2010;62(3):674–82.PubMedGoogle Scholar
  34. 34.
    Emery P, Hamoudeh M, FitzGerald OM, et al. Induction of remission in patients with up to 12 months of moderate-to-severe rheumatoid arthritis symptoms treated with etanercept plus methotrexate over 52 weeks [abstract no. 2549]. Arthritis Rheum. 2012;64:S1077.Google Scholar
  35. 35.
    Emery P, Szumski A, Bukowski J, et al. Characteristics of protocol-specified responders/non-responders treated with etanercept plus methotrexate in Period 1 of the Prize study [abstract no. 426]. In: 77th American College of Rheumatology and the 48th annual meeting of the Association of Rheumatology and Health Professionals; 26–30 Nov 2013; San Diego (CA).Google Scholar
  36. 36.
    Emery P, Spieler W, Stopinska-Polaszewska M, et al. Assessing maintenance of remission after withdrawal of etanercept plus methotrexate, methotrexate alone, or placebo in early rheumatoid arthritis patients who achieved remission with etanercept and methotrexate: the Prize Study [abstract no. 2689]. In: 77th American College of Rheumatology and the 48th annual meeting of the Association of Rheumatology and Health Professionals; 26–30 Oct 2013; San Diego (CA).Google Scholar
  37. 37.
    Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381(9870):918–29.PubMedGoogle Scholar
  38. 38.
    Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675–81.PubMedGoogle Scholar
  39. 39.
    Machado DA, Guzman RM, Xavier RM, et al. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. J Clin Rheumatol. 2014;20(1):25–33.PubMedGoogle Scholar
  40. 40.
    Takeuchi T, Miyasaka N, Zang C, et al. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. Mod Rheumatol. 2013;23(4):623–33.PubMedGoogle Scholar
  41. 41.
    van Riel PLCM, Taggart AJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis. 2006;65(11):1478–83.PubMedCentralPubMedGoogle Scholar
  42. 42.
    van Riel PLCM, Freundlich B, MacPeek D, et al. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis. 2008;67(8):1104–10.PubMedGoogle Scholar
  43. 43.
    Kameda H, Kanbe K, Sato E, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011;38(8):1585–92.PubMedGoogle Scholar
  44. 44.
    Kameda H, Ueki Y, Saito K, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol. 2010;20(6):531–8.PubMedGoogle Scholar
  45. 45.
    Bae S-C, Gun SC, Mok CC, et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskelet Disord. 2013;14:13.PubMedCentralPubMedGoogle Scholar
  46. 46.
    Kim H-Y, Hsu P-N, Barba M, et al. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. Int J Rheum Dis. 2012;15(2):188–96.PubMedGoogle Scholar
  47. 47.
    van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis. 2006;65(3):328–34.PubMedCentralPubMedGoogle Scholar
  48. 48.
    van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54(4):1063–74.PubMedGoogle Scholar
  49. 49.
    Cannon GW, Wang BC, Park GS, et al. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience. Clin Exp Rheumatol. 2013;31(6):919–25.PubMedGoogle Scholar
  50. 50.
    van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(12):3928–39.PubMedGoogle Scholar
  51. 51.
    van der Heijde D, Burmester G, Melo-Gomes J, et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis. 2009;68(7):1113–8.PubMedGoogle Scholar
  52. 52.
    van der Heijde D, Burmester G, Melo-Gomes J, et al. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann Rheum Dis. 2008;67(2):182–8.PubMedGoogle Scholar
  53. 53.
    Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol. 2006;33(5):854–61.PubMedGoogle Scholar
  54. 54.
    Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis. 2006;65(12):1578–84.PubMedCentralPubMedGoogle Scholar
  55. 55.
    Klareskog L, Gaubitz M, Rodríguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29(2):238–47.PubMedGoogle Scholar
  56. 56.
    Pope JE, Haraoui B, Thorne JC, et al. The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis. 2013. doi:10.1136/annrheumdis-2013-203684.Google Scholar
  57. 57.
    Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32.PubMedGoogle Scholar
  58. 58.
    Gottl KH, Gaubitz M, Lange E, et al. A 1-year observational study of the use of etanercept in routine German clinical practice to treat rheumatoid arthritis patients: a health economic, safety and effectiveness evaluation [abstract no. 3.1]. Z Rheumatol. 2013;72:9–10.Google Scholar
  59. 59.
    Iannone F, Gremese E, Gallo G, et al. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clin Rheum. 2014;33(1):31–7.Google Scholar
  60. 60.
    Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21(4):343–51.PubMedCentralPubMedGoogle Scholar
  61. 61.
    Koike T, Harigai M, Inokuma S, et al. Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study. Rheumatol Int. 2012;32(6):1617–24.PubMedCentralPubMedGoogle Scholar
  62. 62.
    Koike T, Harigai M, Inokuma S, et al. Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis. Rheumatol Int. 2012;32(6):1511–9.PubMedCentralPubMedGoogle Scholar
  63. 63.
    Koike T, Harigai M, Inokuma S, et al. Safety and effectiveness of 6 months’ etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs. J Rheumatol. 2013;40(10):1658–68.PubMedGoogle Scholar
  64. 64.
    Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis. 2005;64(2):246–52.PubMedCentralPubMedGoogle Scholar
  65. 65.
    Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(6):1786–94.PubMedGoogle Scholar
  66. 66.
    Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012;71(7):1134–42.PubMedGoogle Scholar
  67. 67.
    Weaver AL, Lautzenheiser RL, Schiff MH, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin. 2006;22(1):185–98.PubMedGoogle Scholar
  68. 68.
    Mori M, Takei S, Imagawa T, et al. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials. Mod Rheumatol. 2011;21(6):572–8.PubMedGoogle Scholar
  69. 69.
    Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology. 2009;48(8):916–9.PubMedGoogle Scholar
  70. 70.
    Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73(6):1114–22.PubMedCentralPubMedGoogle Scholar
  71. 71.
    Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis [Pediatric Rheumatology Collaborative Study Group]. N Engl J Med. 2000;342(11):763–9.PubMedGoogle Scholar
  72. 72.
    Mori M, Takei S, Imagawa T, et al. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan. Mod Rheumatol. 2012;22(5):720–6.PubMedGoogle Scholar
  73. 73.
    Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496–504.PubMedGoogle Scholar
  74. 74.
    Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54(6):1987–94.PubMedGoogle Scholar
  75. 75.
    Ruperto N, Constantin T, Foeldvari I, et al. Long-term safety and efficacy of etanercept in paediatric subjects with extended oligoarticular juvenile idiopathid arthritis, enthesitis-related arthritis, or psoriatic arthritis [abstract no. 280]. In: 77th American College of Rheumatology and the 48th Association of Rheumatology Health Professionals Annual Meeting; 26–30 Oct 2013; San Diego, CAGoogle Scholar
  76. 76.
    Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology. 2012;51(8):1407–15.PubMedGoogle Scholar
  77. 77.
    Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis [Erratum appears in Rheumatology (Oxford). 2011 Apr; 50(4):814]. Rheumatology. 2011;50(1):214–21.PubMedGoogle Scholar
  78. 78.
    Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519–25.PubMedGoogle Scholar
  79. 79.
    Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(12):1638–44.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Halbig M, Horneff G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int. 2009;30(2):229–38.PubMedGoogle Scholar
  81. 81.
    Klotsche J, Minden K, Thon A, et al. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept. Arthritis Care Res. 2014;66(2):253–62.Google Scholar
  82. 82.
    Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26(4):688–92.PubMedGoogle Scholar
  83. 83.
    Otten MH, Prince FHM, Twilt M, et al. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2010;37(3):665–7.PubMedGoogle Scholar
  84. 84.
    Prince FHM, Geerdink LM, Borsboom GJJM, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2010;69(1):138–42.PubMedGoogle Scholar
  85. 85.
    Prince FHM, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68(5):635–41.PubMedGoogle Scholar
  86. 86.
    Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794–804.PubMedGoogle Scholar
  87. 87.
    Tzaribachev N, Kuemmerle-Deschner J, Eichner M, et al. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Rheumatol Int. 2008;28(10):1031–4.PubMedGoogle Scholar
  88. 88.
    Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003;62(3):245–7.PubMedCentralPubMedGoogle Scholar
  89. 89.
    Lamot L, Bukovac LT, Vidovic M, et al. The ‘head-to-head’ comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011;29(1):131–9.PubMedGoogle Scholar
  90. 90.
    Otten MH, Prince FHM, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306(21):2340–7.PubMedGoogle Scholar
  91. 91.
    Solari N, Palmisani E, Consolaro A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40(2):192–200.PubMedGoogle Scholar
  92. 92.
    Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology. 2011;50(1):189–95.PubMedGoogle Scholar
  93. 93.
    Seid M, Opipari L, Huang B, et al. Disease control and health-related quality of life in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:393–9.PubMedGoogle Scholar
  94. 94.
    Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(11):3259–64.PubMedGoogle Scholar
  95. 95.
    Vojvodich PF, Hansen JB, Andersson U. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol. 2007;34:2481–15.Google Scholar
  96. 96.
    Billiau AD, Loop M, Le PQ, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology. 2010;49(8):1550–8.PubMedGoogle Scholar
  97. 97.
    Simonini G, Giani T, Stagi S, et al. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology. 2005;44(6):777–80.PubMedGoogle Scholar
  98. 98.
    Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264–72.PubMedGoogle Scholar
  99. 99.
    Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33(4):712–21.PubMedGoogle Scholar
  100. 100.
    Mease PJ, Woolley JM, Singh A, et al. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol. 2010;37(6):1221–7.PubMedGoogle Scholar
  101. 101.
    Sterry W, Ortonne J-P, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147. doi:10.1136/bmj.c147.PubMedGoogle Scholar
  102. 102.
    Prinz JC, Fitzgerald O, Boggs RI, et al. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. J Eur Acad Dermatol Venereol. 2011;25(5):559–64.PubMedGoogle Scholar
  103. 103.
    Gniadecki R, Robertson D, Molta CT, et al. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol. 2012;26(11):1436–43.PubMedGoogle Scholar
  104. 104.
    Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat. 2006;17(6):343–52.PubMedGoogle Scholar
  105. 105.
    Frankel EH, Strober BE, Crowley JJ, et al. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis. 2007;79:322–6.PubMedGoogle Scholar
  106. 106.
    Gladman DD, Bombardier C, Thorne C, et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol. 2011;38(7):1355–62.PubMedGoogle Scholar
  107. 107.
    Prinz J, Norgauer J, Jobst J, et al. A 1-year observational study of the use of etanercept in routine German clinical practice to treat patients with psoriasis arthritis by rheumatologists and dermatologists: interim analysis [abstract no. 1.6]. Z Rheumatol. 2013;72(Suppl 1):6–7.Google Scholar
  108. 108.
    Bonafede M, Watson C, Fox K, et al. Etanercept and adalimumab treatment patterns after discontinuation within the first year of therapy initiation in psoriasis (PSO) patients in a large managed care population [abstract]. J Am Acad Dermatol. 2012;1(Suppl):AB192.Google Scholar
  109. 109.
    Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011;63(6):1543–51.PubMedGoogle Scholar
  110. 110.
    Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230–6.PubMedGoogle Scholar
  111. 111.
    van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65(12):1572–7.PubMedCentralPubMedGoogle Scholar
  112. 112.
    Braun J, Pavelka K, Ramos-Remus C, et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol. 2012;39(4):836–40.PubMedGoogle Scholar
  113. 113.
    Braun J, McHugh N, Singh A, et al. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology. 2007;46(6):999–1004.PubMedGoogle Scholar
  114. 114.
    Hammoudeh M, Zack DJ, Li W, et al. Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy. J Int Med Res. 2013;41(4):1150–9.PubMedGoogle Scholar
  115. 115.
    Boonen A, Patel V, Traina S, et al. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol. 2008;35(4):662–7.PubMedGoogle Scholar
  116. 116.
    Davis JC Jr, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67(3):346–52.PubMedGoogle Scholar
  117. 117.
    Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis. 2005;64(11):1557–62.PubMedCentralPubMedGoogle Scholar
  118. 118.
    Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013;15(3):R67.PubMedCentralPubMedGoogle Scholar
  119. 119.
    Baraliakos X, Davis J, Tsuji W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum. 2005;52(4):1216–23.PubMedGoogle Scholar
  120. 120.
    van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58(5):1324–31.PubMedGoogle Scholar
  121. 121.
    Dougados M, Braun J, Szanto S, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE) [Erratum appears in Ann Rheum Dis. 2011;70(7):1349]. Ann Rheum Dis. 2011;70(5):799–804.PubMedCentralPubMedGoogle Scholar
  122. 122.
    Dougados M, Braun J, Szanto S, et al. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Rheumatology. 2012;51(9):1687–96.PubMedGoogle Scholar
  123. 123.
    Giardina AR, Ferrante A, Ciccia F, et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int. 2010;30(11):1437–40.PubMedGoogle Scholar
  124. 124.
    Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447–51.PubMedGoogle Scholar
  125. 125.
    Rudwaleit M, van der Heijde D, Landewe R, et al. The devlopment of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–83.PubMedGoogle Scholar
  126. 126.
    Dougados M, van der Heijde D, Sieper J, et al. The symptomatic efficacy and effect on objective signs and symptoms of etanercept in early nonradiographic axial spondyloarthritis. Arth Rheum. 2014. doi:10.1002/art.38721.Google Scholar
  127. 127.
    Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719–26.PubMedGoogle Scholar
  128. 128.
    Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–12.PubMedGoogle Scholar
  129. 129.
    Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. New Engl J Med. 2003;349(21):2014–22.PubMedGoogle Scholar
  130. 130.
    van de Kerkhof PCM, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008;159(5):1177–85.PubMedGoogle Scholar
  131. 131.
    Kemeny L, Amaya M, Cetkovska P, et al. Etanercept therapy provides rapid relief of psoriasis symptoms in patients of Latin America, Eastern Europe, and Asia [abstract no. P062]. J Eur Acad Dermatol Venereol. 2013;27:26–7.Google Scholar
  132. 132.
    Militello G, Xia A, Stevens SR, et al. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006;55(3):517–9.PubMedGoogle Scholar
  133. 133.
    Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S101–11.PubMedGoogle Scholar
  134. 134.
    Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–32.PubMedGoogle Scholar
  135. 135.
    Elewski B, Leonardi C, Gottlieb AB, et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol. 2007;156(1):138–42.PubMedGoogle Scholar
  136. 136.
    Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2013;24(3):169–78.PubMedGoogle Scholar
  137. 137.
    Thaci D, Galimberti R, Amaya-Guerra M, et al. Improvements in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. J Eur Acad Dermatol Venereol. 2013. doi:10.1111/jdv.12207.Google Scholar
  138. 138.
    Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167(3):649–57.PubMedCentralPubMedGoogle Scholar
  139. 139.
    Lebwohl MG, Kircik L, Callis Duffin K, et al. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2013;69(3):385–92.Google Scholar
  140. 140.
    Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–28.PubMedGoogle Scholar
  141. 141.
    Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153(6):1192–9.PubMedGoogle Scholar
  142. 142.
    Reich K, Segaert S, Van de Kerkhof P, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology. 2009;219(3):239–49.PubMedGoogle Scholar
  143. 143.
    Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29–35.PubMedGoogle Scholar
  144. 144.
    Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005;53(5):887–9.PubMedGoogle Scholar
  145. 145.
    Dauden E, Griffiths CEM, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23(12):1374–82.PubMedGoogle Scholar
  146. 146.
    Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health. 2008;11(3):400–7.PubMedGoogle Scholar
  147. 147.
    Ortonne J-P, Griffiths CEM. The efficacy and safety of continuous versus paused etanercept treatment in patients with moderate to severe psoriasis over 54 weeks: the CRYSTEL study. Exp Review Dermatol. 2008;3:657–65.Google Scholar
  148. 148.
    Vender R, Lynde C, Gilbert M, et al. One-year, multicenter, open-label, single-arm study evaluating the safety and effectiveness of etanercept for the treatment of moderate-to-severe plaque psoriasis in a Canadian population. J Cutan Med Surg. 2013;17(2):129–38.PubMedGoogle Scholar
  149. 149.
    Vender R, Lynde C, Ho V, et al. Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy. 2012;10(5):343–53.PubMedGoogle Scholar
  150. 150.
    Vender R, Lynde C, Gilbert M, et al. Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice. J Cutan Med Surg. 2012;16(6):407–16.PubMedGoogle Scholar
  151. 151.
    Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9(8):928–37.PubMedGoogle Scholar
  152. 152.
    Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol. 2012;66(2):e33–45.PubMedGoogle Scholar
  153. 153.
    Puig L, Camacho Martinez FM, Gimeno Carpio E, et al. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up. Dermatology. 2012;225(3):220–30.PubMedGoogle Scholar
  154. 154.
    Bonafede M, Johnson BH, Fox KM, et al. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat. 2013;24(5):369–73.PubMedCentralPubMedGoogle Scholar
  155. 155.
    Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56(4):598–603.PubMedGoogle Scholar
  156. 156.
    Ortonne JP, Taieb A, Ormerod AD, et al. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol. 2009;161(5):1190–5.PubMedGoogle Scholar
  157. 157.
    Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–51.PubMedGoogle Scholar
  158. 158.
    Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63(5):762–8.PubMedGoogle Scholar
  159. 159.
    Siegfried EC, Eichenfield LF, Paller AS, et al. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol. 2010;63(5):769–74.PubMedGoogle Scholar
  160. 160.
    Landells I, Paller AS, Pariser D, et al. Efficacy and safety of etanercept in children and adolescents aged ≥8 years with severe plaque psoriasis. Eur J Dermatol. 2010;20(3):323–8.PubMedGoogle Scholar
  161. 161.
    Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64–70.PubMedGoogle Scholar
  162. 162.
    Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65(3):379–84.PubMedCentralPubMedGoogle Scholar
  163. 163.
    Gottlieb AB, Gordon K, Giannini EH, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol. 2011;10(3):289–300.PubMedGoogle Scholar
  164. 164.
    Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol. 2006;54(3 Suppl 2):S92–100.PubMedGoogle Scholar
  165. 165.
    Pariser DM, Leonardi CL, Gordon K, et al. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012;67(2):245–56.PubMedGoogle Scholar
  166. 166.
    Van der Heijde D, Zack D, Wajdula J, et al. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis. Scand J Rheumatol. 2014;43(1):49–53.PubMedGoogle Scholar
  167. 167.
    Morgan CL, Emery P, Porter D, et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology. 2014;53(1):186–94.PubMedGoogle Scholar
  168. 168.
    Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12(2):225–9.PubMedGoogle Scholar
  169. 169.
    van Dartel SAA, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2013;72(6):895–900.PubMedGoogle Scholar
  170. 170.
    Gibofsky A, Palmer WR, Keystone EC, et al. Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries. J Rheumatol. 2011;38(1):21–8.PubMedGoogle Scholar
  171. 171.
    Ruperto N, Martini A. Juvenile idiopathic arthritis and malignancy. Rheumatology. 2013. doi:10.1093/rheumatology/ket318.PubMedGoogle Scholar
  172. 172.
    Hooper M, Wenkert D, Bitman B, et al. Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports. Pediatrics. 2013;11(1):35.Google Scholar
  173. 173.
    Nardone B, Hammel JA, Raisch DW, et al. Melanoma associated with TNFα inhibitors: a Research on Adverse Drug events And Reports (RADAR) Project. Br J Dermatol. 2014;170(5):1170–2.PubMedGoogle Scholar
  174. 174.
    Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009;68:1177–83.PubMedGoogle Scholar
  175. 175.
    Kimball AB, Pariser D, Yamauchi PS, et al. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2013;68(5):756–64.PubMedGoogle Scholar
  176. 176.
    Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arth Care Res. 2012;64(5):625–39.Google Scholar
  177. 177.
    National Institute for Health and Clinical Excellence. CG79 Rheumatoid arthritis: quick reference guide. 2009. http://guidance.nice.org.uk/CG79/QuickRefGuide/pdf/English. Accessed 18 Apr 2014.
  178. 178.
    Smolen JS, Braun J, Dougados M, et al. Treating spondylarthritis, including ankylosing spondylytis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6–16.PubMedCentralPubMedGoogle Scholar
  179. 179.
    National Institute for Health and Clinical Excellence. TA143 Ankylosing spondylitis: adalimumab, etanercept and infliximab. Quick reference guide. 2008. http://guidance.nice.org.uk/TA143/QuickRefGuide/pdf/English. Accessed 18 Apr 2014.
  180. 180.
    Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896–904.PubMedCentralPubMedGoogle Scholar
  181. 181.
    Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic atrhritis and tuberculosis screening among children receiving biologic medications Arth Care Res. 2013;65(10):1551–63.Google Scholar
  182. 182.
    Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic athritis. Section 6. Guidelines of care for the management of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–74.PubMedGoogle Scholar
  183. 183.
    Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: overview and guidelines of care for treatment with emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–64.PubMedGoogle Scholar
  184. 184.
    Keystone E, Freundlich B, Schiff M, et al. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. J Rheumatol. 2009;36(3):522–31.PubMedGoogle Scholar
  185. 185.
    Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):516–28.PubMedGoogle Scholar
  186. 186.
    Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2013;173:198–206.Google Scholar
  187. 187.
    Emery P, Dorner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of repsonse. Ann Rheum Dis. 2011;70(12):2063–70.PubMedGoogle Scholar
  188. 188.
    Glintborg B, Østergaard M, Krogh NS, et al. Clinical response, drug survival and predictors of response in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72:1149–55.PubMedGoogle Scholar
  189. 189.
    Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med. 2013;173(15):1416–28.PubMedGoogle Scholar
  190. 190.
    Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73(1):75–97.PubMedGoogle Scholar
  191. 191.
    Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology. 2012;51:vi37-vi43.Google Scholar
  192. 192.
    Gibofsky A. Comparative effectiveness of current treatments for rheumatoid arthritis. Am J Manag Care. 2012;18(13 Suppl):S303–14.PubMedGoogle Scholar
  193. 193.
    Pompili M, Biolato M, Miele L, et al. Tumour necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol. 2013;19(44):7867–73.PubMedCentralPubMedGoogle Scholar
  194. 194.
    Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2011;150:124–31.Google Scholar
  195. 195.
    Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69:380–6.PubMedCentralPubMedGoogle Scholar
  196. 196.
    Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arth Rheum. 2002;46:2287–93.Google Scholar
  197. 197.
    Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68:648–53.PubMedGoogle Scholar
  198. 198.
    Dixon WG, Watson KD, Lunt M, et al. Influence of anti-tumour necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheuamtology Biologics Register. Arth Care Res. 2010;62(6):755–63.Google Scholar
  199. 199.
    Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Safety. 2011;20(2):119–30.Google Scholar
  200. 200.
    Le Blay P, Mouterde G, Bametche G, et al. Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol. 2012;30(5):756–64.PubMedGoogle Scholar
  201. 201.
    Cawson MR, Mitchell SA, Knight C, et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord. 2014. doi:10.1186/1471-2474-15-26.PubMedCentralPubMedGoogle Scholar
  202. 202.
    Doan QV, Chiou C-F, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12(7):555–69.PubMedGoogle Scholar
  203. 203.
    Jamsen E, Virta LJ, Hakala M, et al. The decline in joint replacement surgery in rheumatoid arthritis with a concomitant increase in the intensity of anti-rheumatic therapy. Acta Orthop. 2013;84(4):331–7.PubMedCentralPubMedGoogle Scholar
  204. 204.
    Harty LC, O’Toole G, Bennett K, et al. Prescription of tumour necrosis factor α antagonists is strongly associated with a reduction in hospital admissions and in musculoskeletal surgical procedures for rheumatoid arthritis based on 16 year analysis of nationwide data [abstract no. 2540]. Arth Rheum. 2012;64(10 Suppl):S1072.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations